Topikal leverans av biologiska läkemedel för hudföryngring
| Reference number | |
| Coordinator | Kungliga Tekniska Högskolan - KTH Skolan för elektroteknik och datavetenskap |
| Funding from Vinnova | SEK 1 000 000 |
| Project duration | November 2024 - October 2025 |
| Status | Ongoing |
| Venture | Preparation projects for international application within health |
| Call | Towards deeper collaboration with UK and USA partners within Health and Life Science |
Purpose and goal
The project aims to promote dermatological treatments through collaboration between Turn Bio and KTHs Morningstar, a platform for topical drug delivery. The focus is on validating an innovative drug delivery platform that uses ultra-sharp microspheres to painlessly deliver large molecules, such as mRNA, directly into the skin. This method lacks the limitations of traditional methods by offering a minimally invasive, precise and patient-friendly solution for various skin conditions.
Expected effects and result
We intend to demonstrate the effect of our new delivery technology in combination with Turn Bio´s active substance in a model tissue. We also intend to sign a collaboration and commercialization agreement with Turn bio that will better prepare us for other potential customers. By leveraging research expertise and infrastructure from both Sweden and the USA, we hope to be able to open new markets and strengthen Swedish competitiveness in the life science sector.
Planned approach and implementation
In close dialogue with Turn Bio, we will test their formulation TRN-001 (an mRNA cocktail) with our microsphere technology. We intend to set up methods using the ´living´ model skin TenSkin from an Irish company which will enable us to evaluate biodistribution and expression in the tissue. We also plan to test our technology at Turn Bio´s premises in California.